Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL275602 | 0.80 | MAPK1 (0.37) | MAPK1P2RX7 | |
| SCHEMBL20478093 | 0.79 | MAPK1 (0.31) | MAPK1 | |
| SCHEMBL27155067 | 0.77 | P2RX7 (0.40) | MAPK1P2RX7 | |
| SCHEMBL24700432 | 0.76 | USP30 (0.37) | MAPK1P2RX7 | |
| SCHEMBL30050499 | 0.76 | USP30 (0.37) | MAPK1P2RX7 | |
| SCHEMBL21199572 | 0.74 | MAPK1 (0.36) | MAPK1P2RX7 | |
| SCHEMBL21199575 | 0.74 | MAPK1 (0.36) | MAPK1P2RX7 | |
| SCHEMBL1804491 | 0.73 | MAPK1 (0.36) | MAPK1P2RX7 | |
| SCHEMBL16597739 | 0.72 | P2RX7 (0.36) | MAPK1P2RX7F2F11PRSS1 | |
| SCHEMBL19253107 | 0.72 | MAPK1 (0.32) | MAPK1P2RX7F2F11PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4466266-B1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | TRANSNEURAL THERAPEUTICS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260000692-A1 | Substituted N-(Pyridin-2-yl)Acetamide Derivatives as CDK12/13 Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2026-01-01 | — | — | US | disclosed |
| US-12486268-B2 | Fused heterocycles as 5-HT2A receptor agonists | Transneural Therapeutics, Inc. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12459944-B2 | Fused heterocycles as 5-HT2A receptor agonists | Transneural Therapeutics, Inc. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250243199-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | Transneural Therapeutics, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20250032476-A1 | ALPHA-2A ADRENERGIC RECEPTOR MODULATORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2025-01-30 | — | — | US | disclosed |
| US-20240425503-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | Transneural Therapeutics, Inc. | 2024-12-26 | — | — | US | disclosed |
| US-20240246969-A1 | HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-25 | — | — | US | disclosed |
| EP-4027995-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| US-11078201-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11034694-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-06-15 | — | — | US | disclosed |
| US-11021481-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210087189-A1 | SUBSTITUTED ISINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,3-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20210087190-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-25 | — | — | US | disclosed |
| WO-2021055612-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL-BioTech Investments, Inc. (US) | 2021-03-25 | — | — | WO | disclosed |
| US-20210078997-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROL[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| US-20210078996-A1 | HPK1 ANTAGONISTS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| WO-2021050964-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459944-B2 | Fused heterocycles as 5-HT2A receptor agonists | HTR2A, HTR2C, HTR5A | MAPK1 2678/4885P2RX7 82/4885F2 3770/4885 |
| US-20260000692-A1 | Substituted N-(Pyridin-2-yl)Acetamide Derivatives as CDK12/13 Inhibitors | CDK1, CDK12, CDK11A | MAPK1 286/4885P2RX7 4619/4885F2 4265/4885 |
| US-20240246969-A1 | HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS | CAMKK2, CAMKK1, CAMK1 | MAPK1 372/4885P2RX7 2132/4885F2 4279/4885 |
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, DYRK2, DYRK1A | MAPK1 1860/4885P2RX7 3693/4885F2 3097/4885 |
| US-20250243199-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | HTR2A, HTR2C, HTR5A | MAPK1 2678/4885P2RX7 82/4885F2 3770/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | MAPK1 1801/4885P2RX7 1964/4885F2 4256/4885 |
| US-20240425503-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | HTR2A, HTR2C, HTR1A | MAPK1 3023/4885P2RX7 109/4885F2 3340/4885 |
| US-20250032476-A1 | ALPHA-2A ADRENERGIC RECEPTOR MODULATORS AND USES THEREOF | ADRA2A, ADRB2, ADRA2C | MAPK1 4134/4885P2RX7 369/4885F2 4364/4885 |
| US-20210087190-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, IP6K1 | MAPK1 526/4885P2RX7 1379/4885F2 3857/4885 |
| US-20210078997-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROL[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, IP6K1 | MAPK1 535/4885P2RX7 1591/4885F2 3784/4885 |
| US-20210078996-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | MAPK1 795/4885P2RX7 2163/4885F2 4235/4885 |
| US-11021481-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | HIPK1, PDXK, IP6K1 | MAPK1 526/4885P2RX7 1379/4885F2 3857/4885 |
| US-12486268-B2 | Fused heterocycles as 5-HT2A receptor agonists | HTR2A, HTR2C, HTR5A | MAPK1 2678/4885P2RX7 82/4885F2 3770/4885 |
| US-11078201-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists | HIPK1, PDXK, IP6K1 | MAPK1 535/4885P2RX7 1591/4885F2 3784/4885 |
| US-20210087189-A1 | SUBSTITUTED ISINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,3-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, SIK1 | MAPK1 468/4885P2RX7 1295/4885F2 4114/4885 |
| US-11034694-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | HIPK1, IP6K1, PDXK | MAPK1 478/4885P2RX7 1112/4885F2 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.